TD Cowen downgraded NGM Biopharmaceuticals to Market Perform from Outperform with a price target of $1.55, down from $4, after the company announced a merger agreement with affiliates of The Column Group, the company’s largest shareholder, for $1.55 per share.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NGM:
- NGM Biopharmaceuticals Acquisition by Atlas Neon Parent
- NGM Biopharmaceuticals trading resumes
- NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
- NGM to be acquired by affiliates of The Column Group for $1.55 per share
- NGM Biopharmaceuticals trading halted, news pending
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue